Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company
focused on developing and commercializing products for the treatment of
CNS diseases, announced that following a seven-day bench trial, Judge
Renee Marie Bumb of the United States District Court for the District of
New Jersey ruled that Actavis Inc. and its subsidiaries infringed US
Patent Nos. 7,722,898 and 7,910,131 by submitting to the FDA an ANDA
seeking permission to market a generic version of Oxtellar XR before the
expiration of Supernus' patents. Judge Bumb also ruled that US Patent
Nos. 7,722,898, 7,910,131, and 8,617,600 are valid. The FDA's Orange
Book lists all three patents as expiring on April 13, 2027.
"We are pleased with the court's ruling that Actavis will infringe two of our patents on Oxtellar XR, and the finding that all three patents are valid," stated Jack Khattar, president and chief executive officer of Supernus Pharmaceuticals. "We will continue to vigorously defend our novel products and build upon our strong intellectual property to provide our products the protection they are entitled to."
"We are pleased with the court's ruling that Actavis will infringe two of our patents on Oxtellar XR, and the finding that all three patents are valid," stated Jack Khattar, president and chief executive officer of Supernus Pharmaceuticals. "We will continue to vigorously defend our novel products and build upon our strong intellectual property to provide our products the protection they are entitled to."
No comments:
Post a Comment